**From:** xxxxx xxxxxxxx xxxxx@fightbladdercancer.co.uk  
**Sent:** 19 June 2020 15:16  
**To:** xxxxx xxxxx xxxxxxxxxxx@nice.org.uk  
**Cc:** xxxxxxxxx xxxx xxxxxxxxxxxxxx@nice.org.uk>  
**Subject:** Re: Final Appraisal Determination – Pembrolizumab for previously treated advanced or metastatic urothelial cancer (CDF review TA519) [ID1536]

Dear xx xxxxxx and Dr Makarem,

Thank-you for taking the time to respond to our Appeal Letter for Pembrolizumab for previously treated advanced or metastatic urothelial cancer (CDF review TA519) [ID1536].  
  
If it would be possible to observe the appeal hearing remotely, I would greatly appreciate it.

Fight Bladder Cancer will not be making a further submission.  
  
Warmest regards,  
  
xx xxxxx xxxxxxxx, PhD

CEO

Fight Bladder Cancer

Xx xxxxx xxxxxxxx, PhD

**CEO**

To receive the latest updates on the charity's work, please sign up here >> [www.fightbladdercancer.co.uk/contact-preferences](http://www.fightbladdercancer.co.uk/contact-preferences)

she/her

Mobile: +44 (0) xxxx xxx xxx

Office: +44 (0) 1844 351621

xxxxx[@fightbladdercancer.co.uk](mailto:lydia@fightbladdercancer.co.uk)

[www.fightbladdercancer.co.uk](http://www.fightbladdercancer.co.uk)